三叶草生物曾押下重注的新冠疫苗不仅没带来如期的商业回报,还让公司卷入一场超2亿美元的追债风波。 事情得从4年前说起——2021年,三叶草香港公司与全球疫苗免疫联盟(Gavi)订立预购协议,后者至多需购买4.14亿剂COVID-19候选疫苗SCB-2019(CpG 1018加铝佐剂),通过新冠肺炎疫苗实施计划(COVAX)机制分配给全球参与国。随后,该协议经修订转换为6400万剂SCB-2019的...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.